The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.
|Articles|August 12, 2020
Advocacy Center
Use NAPNAP’s Advocacy Center to stay up to date on our priority child health and practice legislation.
Advertisement
Use NAPNAP’s
Advertisement
Related to this article
FDA approved obinutuzumab for relapsing or steroid-dependent childhood-onset INS, based on INShore data showing 95.5% vs 73.2% sustained remission.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
Jonathan Miller, MD, discusses earlier HPV vaccination, individualized conversations with hesitant families, and strategies to improve vaccine uptake.
Jonathan Miller, MD, discusses factors behind lagging HPV vaccination rates and how pediatricians can address common parent concerns.
In a Hirschsprung disease mouse model, diet shifted gut microbes and inflammation, with a 3-fold survival difference between standard diets.
The latest IDSA histoplasmosis update adds a consensus statement on severe disease and outlines when children with pulmonary infection warrant itraconazole therapy.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA approves baricitinib for adolescents with severe alopecia areata
2
FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
3
Contemporary Pediatrics week in review: September 21-25, 2026
4
Starting HPV vaccination earlier gives pediatricians more opportunities to protect children
5